argenex SE $ARGX Stock Position Increased by Fiera Capital Corp

Fiera Capital Corp grew its position in argenex SE (NASDAQ:ARGX) by 12.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 177,654 shares of the company’s stock after purchasing an additional 19,180 shares during the period. Fiera Capital Corp’s holdings in argenex were worth $131,030,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. NewEdge Wealth LLC bought a new stake in shares of argenex during the third quarter valued at approximately $223,000. Syon Capital LLC increased its position in argenex by 9.6% in the 3rd quarter. Syon Capital LLC now owns 966 shares of the company’s stock valued at $712,000 after acquiring an additional 85 shares during the period. Axxcess Wealth Management LLC bought a new stake in argenex during the 3rd quarter valued at $247,000. BBR Partners LLC acquired a new position in argenex during the 3rd quarter worth $214,000. Finally, Beirne Wealth Consulting Services LLC acquired a new position in argenex during the 3rd quarter worth $506,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Performance

NASDAQ ARGX opened at $847.26 on Friday. The stock has a market capitalization of $52.43 billion, a P/E ratio of 36.38, a P/E/G ratio of 0.73 and a beta of 0.37. The business’s fifty day moving average is $831.90 and its two-hundred day moving average is $804.81. argenex SE has a 1 year low of $510.05 and a 1 year high of $934.62.

Analyst Upgrades and Downgrades

ARGX has been the topic of a number of research analyst reports. DZ Bank raised argenex to a “strong-buy” rating in a report on Friday, December 19th. Wedbush reissued an “outperform” rating and set a $1,000.00 target price on shares of argenex in a research note on Wednesday, January 14th. Stifel Nicolaus raised their price objective on shares of argenex from $1,028.00 to $1,248.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. HC Wainwright upped their target price on argenex from $774.00 to $915.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Truist Financial increased their price target on argenex from $950.00 to $1,030.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $986.78.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.